Anticoagulation in Patients With Venous Thromboembolism and Cancer (VICTORIE)
VICTORIE (VTE IN CANCER - TREATMENT, OUTCOMES AND RESOURCE USE IN EUROPE)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- A VTE diagnosis
- Active cancer or history of cancer
- Treatment with VKA, NOAC (apixaban, rivaroxaban, dabigatran, edoxaban) or LMWH
- Age ≥ 18 years at the date of index VTE (Venous thromboembolic)
Exclusion Criteria:
- Prior VTE diagnosis
- Diagnosis of prior atrial fibrillation
- Inferior Vena Cava (IVC) filter
- Prior exposure to (OAC) oral anticoagulation or (PAC)parenteral anticoagulation - note: Prophylactic use of (OAC)/(PAC) allowed.
- Pregnancy
- More than one (OAC) oral anticoagulation or (PAC) parenteral anticoagulation dispensed on the index date.
- Patients with less than one day of follow up
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
VTE and history of cancer
|
Dabigatran
Edoxaban
Anticoagulant
Anticoagulant
Vitamin K antagonist
Low Molecular Weight Heparin
|
|
VTE and active cancer
|
Dabigatran
Edoxaban
Anticoagulant
Anticoagulant
Vitamin K antagonist
Low Molecular Weight Heparin
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recurrence of Thromboembolism
Time Frame: 6 Months after treatment began as early as 1/1/2013
|
The follow-up period during which outcome events of interest will be identified will run from the day after the index date until the end of the data collection or death, whichever occurs first.
As data are updated at different times and frequencies in the different study countries, the date of the end of data collection will be determined after the relevant permissions have been acquired from the respective authorities.
|
6 Months after treatment began as early as 1/1/2013
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Embolism and Thrombosis
- Thromboembolism
- Neoplasms
- Embolism
- Venous Thromboembolism
- Sulfur Compounds
- Organic Chemicals
- Pyridines
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Benzimidazoles
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Carbohydrates
- Heparin
- Glycosaminoglycans
- Polysaccharides
- Morpholines
- Oxazines
- Thiophenes
- Rivaroxaban
- Dabigatran
- Heparin, Low-Molecular-Weight
- apixaban
- edoxaban
Other Study ID Numbers
Other Study ID Numbers
- B0661150
- VICTORIE (Other Identifier: Alias Study Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.